Codexis, Inc. CDXS · Stock Open Codexis, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Codexis, Inc. Analysis (CDXS)
Is Codexis, Inc. a good investment? Codexis, Inc. (CDXS) is currently trading at 1.41 USD. Market analysts have a consensus price target of 6.14 USD. This suggests a potential upside from current levels.
Earnings Schedule: Codexis, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.32.
Investor FAQ
Does Codexis, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Codexis, Inc.?
Codexis, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.33.
Company Profile
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Community Discussion